Company news

Valbiotis SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

VALBIOTIS SA: Valbiotis opens a new growth driver with the launch of its full product range on Amazon France

October 25, 2026

VALBIOTIS SA: Valbiotis receives double “Best Pharma Product 2027” award for its ValbiotisPRO® Cholestérol and ValbiotisPRO® Santé Métabolique solutions

October 18, 2026

VALBIOTIS SA: First-half 2026 results

October 12, 2026

VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23

September 22, 2026

VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63

July 22, 2026

VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M

June 26, 2026

VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%

June 8, 2026

VALBIOTIS SA: Valbiotis continues its expansion in Asia

May 11, 2026

VALBIOTIS SA: Valbiotis expands its e-commerce to Belgium and Luxembourg

April 23, 2026

VALBIOTIS SA: General Meeting of April 17, 2026: All Resolutions Approved

April 17, 2026

VALBIOTIS SA: Valbiotis announces launch of operations in Asia

March 19, 2026

VALBIOTIS SA: 2025 Financial Results

March 2, 2026

VALBIOTIS SA: Valbiotis expands its ValbiotisPLUS® range with the new Menopause & Perimenopause solution

February 2, 2026

VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4

January 27, 2026

VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges

January 26, 2026

VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)

January 12, 2026

VALBIOTIS SA: Valbiotis announces an exclusive distribution agreement in the Middle East

January 8, 2026

VALBIOTIS SA: Valbiotis recognized by the 2025 Top Santé Award for Valbiotis Plus® Serenity, an innovative solution for emotional balance

December 18, 2025

VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)

December 8, 2025

VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia

November 17, 2025

VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap

October 9, 2025

Decks

The 5 newest of 20 decks. Every deck is listed under its year.